Categories Covered:Adverse Events, Comorbidities, and HIV, Providing Quality HIV Care, Meeting the Costs of HIV Care, HIV, Discrimination, and Law, HIV Treatments in Development, HIV Case Management and Social Work, HIV in the Arts, HIV Treatment Strategies, HIV Prevention Methods, HIV Care and Services Outside the US, Disclosing Your HIV Status, HIV Stigma and Discrimination, Newly Diagnosed, HIV/AIDS Basics, HIV in Film, TV, and Media, HIV Treatment and Medical Care, HIV Policy and Advocacy, People Over 50, Women, PrEP (HIV Pre-Exposure Prophylaxis), HIV/AIDS Outside the U.S., Myths About HIV/AIDS, HIV Epidemiology, Gay Men, Regional/Global Anti-HIV Efforts, Starting HIV Treatment and Medical Care, Switching or Stopping HIV Treatment, Non-Medical HIV Prevention, Pregnancy, Childbirth, and HIV, HIV Testing, HIV in Arts and Entertainment, HIV Testing, Non-HIV Sexually Transmitted Infections, HIV-Related Policy Issues, Substance Use and Harm Reduction for HIV, Relationships and Sex, People Under 30, HIV Prevention and Transmission, Financial Issues, Living Well With HIV, PrEP (HIV Pre-Exposure Prophylaxis), African-Americans, HIV and Mental Health Care, First-Line HIV Treatment, HIV Basic Science and Pathogenesis, HIV in Specific Countries, Curing HIV, HIV/AIDS Statistics, Other Populations, Efavirenz (Sustiva, Stocrin), HIV in the Trump Era, Conceiving and Having a Baby
Reseearchers have discovered that very rare interferons, only found in hunter-gatherers from central Africa, are far better able to inhibit HCV infection.
"The fight against AIDS is at a tipping point," Maureen Miller writes. "Increasingly, there are signs that we may be heading in the wrong direction."
"The operation, and subsequent events, have put us on the cusp of new insights and understanding about HIV and its transmission," Caroline T. Tiemessen writes.
A Chinese scientist claims to have edited human DNA to make us more resistant to HIV. Here's why that's not good news.
"We are not yet at the stage where aspirin can be recommended for preventing HIV, but the potential for another tool in our belt against a virus that has killed 35 million people (almost the population of Canada), can only be good news."
"A new approach is being piloted. The idea is to test if point-of-care viral load monitoring is in reach."
The number of new hepatitis B virus and hepatitis C virus infections in the U.S. has been decreasing for many years, but this trend has been reversed during recent years due to the opioid epidemic as more people use injection drugs, share needles or ...